disease modifying antirheumatic drugs

disease modifying antirheumatic drugs (DMARD),

agents that apparently alter the course and progression of rheumatoid arthritis, as opposed to more rapidly acting substances that suppress inflammation and decrease pain, but do not prevent cartilage or bone erosion or progressive disability.
References in periodicals archive ?
This study also underlines the importance of rigorous control of inflammation with disease modifying antirheumatic drugs, not only for the management of joint symptoms but also to reduce the need for drugs with potential adverse cardiovascular effects and, ultimately to diminish the inflammation driven atherothrombotic process," they emphasized.
fter five years, 97 pc of the patients had been treated with disease modifying antirheumatic drugs (DMARDs), reducing both the chemical markers of inflammation and the physical appearance of their arthritis.
Kineret is intended for patients at least 18 years of age who have not responded to one or more drugs referred to as disease modifying antirheumatic drugs.
Doctors most commonly prescribe or administer corticosteroids, vitamin D analogues, and combination products for psoriasis, while disease modifying antirheumatic drugs (DMARDs) are preferred for rheumatoid arthritis, says the analyst of this research.
24-Week Results of a Blinded Phase IIb Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1 / Janus Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Kineret is for patients at least 18 years of age who have not responded to one or more drugs referred to as DMARDs or disease modifying antirheumatic drugs.
Food and Drug Administration has approved Kineret(TM) (anakinra) for the reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) in adult patients who have failed one or more disease modifying antirheumatic drugs (DMARDs).
In 2002, HUMIRA was approved to reduce signs and symptoms and inhibit the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease modifying antirheumatic drugs (DMARDs).
Food and Drug Administration (FDA) for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more disease modifying antirheumatic drugs (DMARDS).
A Phase III study has been initiated that will evaluate HUMIRA in improving signs and symptoms of psoriatic arthritis in adult patients with moderate to severe disease who have had inadequate response to disease modifying antirheumatic drugs (DMARDs).
HUMIRA is the first human monoclonal antibody approved by the FDA for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs).
HUMIRA is the first human monoclonal antibody approved for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active RA who have had insufficient response to one or more traditional disease modifying antirheumatic drugs (DMARDs).

Full browser ?